-+ 0.00%
-+ 0.00%
-+ 0.00%

Wisdom Pharmaceutical announced that Beihai Wisdom Venture Capital Co., Ltd., a wholly-owned subsidiary of the company, signed a partnership agreement with Shanghai Bainuo Private Equity Fund Management Co., Ltd. and other limited partners to pledge the investment of Wuhan Bainuo Jiatai Venture Capital Partnership with its own capital of 10 million yuan, accounting for 29.24% of the total amount of capital pledged by the partnership. The fund has a size of 34.2 million yuan. It is still in the fundraising stage. It has not yet obtained a registration from the China Securities Investment Fund Industry Association. In the future, it is necessary to apply for industrial and commercial change registration and fund filing. The fund plans to invest in the form of subscribing to the additional registered capital of Guangzhou Kentai Biomedical Technology Co., Ltd., which focuses on the original innovation of kinase inhibitors.

Zhitongcaijing·11/03/2026 10:25:07
Listen to the news
Wisdom Pharmaceutical announced that Beihai Wisdom Venture Capital Co., Ltd., a wholly-owned subsidiary of the company, signed a partnership agreement with Shanghai Bainuo Private Equity Fund Management Co., Ltd. and other limited partners to pledge the investment of Wuhan Bainuo Jiatai Venture Capital Partnership with its own capital of 10 million yuan, accounting for 29.24% of the total amount of capital pledged by the partnership. The fund has a size of 34.2 million yuan. It is still in the fundraising stage. It has not yet obtained a registration from the China Securities Investment Fund Industry Association. In the future, it is necessary to apply for industrial and commercial change registration and fund filing. The fund plans to invest in the form of subscribing to the additional registered capital of Guangzhou Kentai Biomedical Technology Co., Ltd., which focuses on the original innovation of kinase inhibitors.